METROL-XL 23.75 metoprolol succinate 23.75 mg modified release tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

metrol-xl 23.75 metoprolol succinate 23.75 mg modified release tablet blister pack

arrotex pharmaceuticals pty ltd - metoprolol succinate, quantity: 23.75 mg - tablet, modified release - excipient ingredients: titanium dioxide; glycerol; magnesium stearate; microcrystalline cellulose; stearic acid; ethylcellulose; maize starch; hypromellose; methylcellulose - stable, chronic heart failure as an adjunct to other heart failure therapy.

TOPROL-XL metoprolol succinate 23.75mg controlled release tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

toprol-xl metoprolol succinate 23.75mg controlled release tablet blister pack

astrazeneca pty ltd - metoprolol succinate, quantity: 23.75 mg - tablet, modified release - excipient ingredients: silicon dioxide; ethylcellulose; hyprolose; microcrystalline cellulose; sodium stearylfumarate; synthetic paraffin; macrogol 6000; hypromellose; titanium dioxide - stable, chronic heart failure as an adjunct to other heart failure therapy.

TOBETA-XL metoprolol succinate 23.75 mg modified release tablet bottle pack Australia - English - Department of Health (Therapeutic Goods Administration)

tobeta-xl metoprolol succinate 23.75 mg modified release tablet bottle pack

pharmacor pty ltd - metoprolol succinate, quantity: 23.75 mg - tablet, modified release - excipient ingredients: microcrystalline cellulose; ethylcellulose; triethyl citrate; silicified microcrystalline cellulose; methacrylic acid copolymer; sodium stearylfumarate; macrogol 6000; povidone; purified talc; croscarmellose sodium; silicon dioxide; titanium dioxide; hypromellose; peg-150 distearate; lauromacrogol 400 - stable, chronic heart failure as an adjunct to other heart failure therapy.

TOPRELOC-XL metoprolol succinate 23.75 mg modified release tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

topreloc-xl metoprolol succinate 23.75 mg modified release tablet blister pack

pharmacor pty ltd - metoprolol succinate, quantity: 23.75 mg - tablet, modified release - excipient ingredients: macrogol 6000; ethylcellulose; sodium stearylfumarate; silicon dioxide; triethyl citrate; microcrystalline cellulose; purified talc; methacrylic acid copolymer; croscarmellose sodium; povidone; silicified microcrystalline cellulose; titanium dioxide; hypromellose; peg-150 distearate; lauromacrogol 400 - stable, chronic heart failure as an adjunct to other heart failure therapy.

TOPRELOC-XL  metoprolol succinate 23.75 mg modified release tablet bottle Australia - English - Department of Health (Therapeutic Goods Administration)

topreloc-xl metoprolol succinate 23.75 mg modified release tablet bottle

pharmacor pty ltd - metoprolol succinate, quantity: 23.75 mg - tablet, modified release - excipient ingredients: triethyl citrate; macrogol 6000; croscarmellose sodium; povidone; sodium stearylfumarate; purified talc; silicon dioxide; silicified microcrystalline cellulose; methacrylic acid copolymer; ethylcellulose; microcrystalline cellulose; titanium dioxide; hypromellose; peg-150 distearate; lauromacrogol 400 - stable, chronic heart failure as an adjunct to other heart failure therapy.

TOBETA-XL metoprolol succinate 23.75 mg modified release tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

tobeta-xl metoprolol succinate 23.75 mg modified release tablet blister pack

arrotex pharmaceuticals pty ltd - metoprolol succinate, quantity: 23.75 mg - tablet, modified release - excipient ingredients: purified talc; macrogol 6000; microcrystalline cellulose; povidone; silicon dioxide; triethyl citrate; sodium stearylfumarate; croscarmellose sodium; silicified microcrystalline cellulose; methacrylic acid copolymer; ethylcellulose; titanium dioxide; hypromellose; peg-150 distearate; lauromacrogol 400 - stable, chronic heart failure as an adjunct to other heart failure therapy.

TEMPO RESIDUAL INSECTICIDE Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

tempo residual insecticide

2022 environmental science au pty ltd - betacyfluthrin - suspension concentrate - betacyfluthrin pyrethroid active 25.0 g/l - insecticide - agricultural/farm buildings | azalea | barracks | commercial area - outdoors | commercial building/structure - external | commer - african black beetle | ant | aphid | argentine stem weevil | armyworm | bed bug | bill bug | carpet beetle | caterpillar | clothes moth | cockroach | common housefly | cricket | cutworm | flea | fly | garden or south african vine weevil | grasshopper | lesser mealworm | millipede | mosquito | paper nest wasp | paralysis tick | sawfly - larva | silverfish | spider - non-web spinning | spider - web spinning | stored product insect pests - see label | thrip | webworm | whitefly | adult mosquitoes | argentine ant | australian paralysis tick | bedbug | billbug | black beetle | black house spider | budworm | ctenocephalides spp. | darkling beetle | garden weevil | ground fleas | house fly | la plata weevil | large cockroach | litter beetle | looper | niditinea spp. | papernest wasps | pharaoh ant | scrub tick | small cockroach | south african vine weevil | spodoptera spp. | stored product pests | thrips spp. | tinea spp. | tineola spp.

OZCROP ATRAZINE 500 SC HERBICIDE Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

ozcrop atrazine 500 sc herbicide

oz crop pty ltd - atrazine; ethylene glycol - suspension concentrate - atrazine triazine active 500.0 g/l; ethylene glycol solvent other 50.0 g/l - herbicide - broom millet | canola(tt varieties only) - pre emergent | canola-triazine tolerant only-post emerg | eucalyptus plantation | fal - amaranth or amaranthus | annual grass weed - suppression | annual ryegrass | annual ryegrass - suppression | barley grass | barley grass - suppression | barnyard or water grass | billygoat weed or blue top | black bindweed | blackberry nightshade | bladder ketmia | broadleaf weeds | broadleaf weeds and grasses | brome grass | brome grass - suppression | budda or butter pea | burr | caltrop or yellow vine | capeweed | charlock | clover | cobbler's pegs | common pigweed | common thornapple | corn gromwell, ironweed or sheepweed | crowsfoot grass | cruciferous weed | dock | dwarf marigold | fat hen | feathertop rhodes grass | flannel weed - sida cordifolia | fumitory | geranium | giant or black pigweed | giant sensitive plant | ground or annual ground cherry | ivy leaf speedwell | liverseed or urochloa grass | london rocket | loosestrife | lovegrass | medic | mexican or prickly poppy | mintweed | mouse-ear chickweed | mustard | paddy melon | parthenium weed | paterson's curse | pigeon grass | pigweed spp. | plai

PNEUMOVAX 23 pneumococcal purified capsular polysaccharides 25 microgram/0.5mL injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

pneumovax 23 pneumococcal purified capsular polysaccharides 25 microgram/0.5ml injection vial

merck sharp & dohme (australia) pty ltd - pneumococcal purified capsular polysaccharides, quantity: 50 microgram/ml - injection, solution - excipient ingredients: water for injections; phenol; sodium chloride - pneumovax 23 is indicated for immunisation of individuals in the following situations: all individuals over the age of 65 years; individuals with asplenia, either functional or anatomical, including sickle cell disease, in persons more than 2 years of age; where possible the vaccine should be given at least 14 days before splenectomy; immunocompromised patients at increased risk of pneumococcal disease (eg patients with hiv infection before the development of aids, nephrotic syndrome, multiple myeloma, lymphoma, hodgkin's disease and organ transplantation); aboriginal and torres strait islander people over 50 years of age; immunocompetent persons at increased risk of complications from pneumococcal disease because of chronic illness (eg chronic cardiac, renal or pulmonary disease, diabetes mellitus, alcoholism and cirrhosis); patients with cerebrospinal fluid leaks. in australia, the national health and medical research council (nhmrc) currently recommends the vaccination of tobacco smokers with the 23-valent